DE69530004D1 - Transdermale verabreichung von apomorphin - Google Patents

Transdermale verabreichung von apomorphin

Info

Publication number
DE69530004D1
DE69530004D1 DE69530004T DE69530004T DE69530004D1 DE 69530004 D1 DE69530004 D1 DE 69530004D1 DE 69530004 T DE69530004 T DE 69530004T DE 69530004 T DE69530004 T DE 69530004T DE 69530004 D1 DE69530004 D1 DE 69530004D1
Authority
DE
Germany
Prior art keywords
apomorphine
transdermal administration
transdermal
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69530004T
Other languages
English (en)
Other versions
DE69530004T2 (de
Inventor
Franck Durif
Ragab El-Rashidy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69530004D1 publication Critical patent/DE69530004D1/de
Publication of DE69530004T2 publication Critical patent/DE69530004T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
DE69530004T 1994-12-23 1995-12-22 Transdermale verabreichung von apomorphin Expired - Fee Related DE69530004T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/362,831 US5562917A (en) 1994-12-23 1994-12-23 Transdermal administration of apomorphine
US362831 1994-12-23
PCT/US1995/016798 WO1996019956A1 (en) 1994-12-23 1995-12-22 Transdermal administration of apomorphine

Publications (2)

Publication Number Publication Date
DE69530004D1 true DE69530004D1 (de) 2003-04-24
DE69530004T2 DE69530004T2 (de) 2004-03-04

Family

ID=23427711

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530004T Expired - Fee Related DE69530004T2 (de) 1994-12-23 1995-12-22 Transdermale verabreichung von apomorphin

Country Status (4)

Country Link
US (2) US5562917A (de)
EP (1) EP0800364B1 (de)
DE (1) DE69530004T2 (de)
WO (1) WO1996019956A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
WO1999009828A1 (en) * 1997-08-25 1999-03-04 Pentech Pharmaceuticals, Inc. Method for amelioration of social phobia
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6280851B1 (en) * 1998-03-23 2001-08-28 Sentrex Company, Inc. Multilayer product for printed circuit boards
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
KR20030036157A (ko) 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법
MXPA02010542A (es) * 2000-04-26 2003-10-14 Watson Pharmaceuticals Inc Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
EP1341536A4 (de) 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc Behandlung von durch antidepressiva ausgelöster sexueller dysfunktion mit apomorphin
KR20030074810A (ko) * 2001-02-08 2003-09-19 파마시아 코포레이션 성 기능장애의 치료를 위한 신속-발현 약
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
EP1496915A1 (de) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycosid und orthoester-glycosid-derivate von apomorphin, analoga und ihre verwendungen
DK2561860T3 (en) * 2002-05-31 2018-04-30 Titan Pharmaceuticals Inc Implantable polymer device for prolonged release of buprenorphine
SE522979C2 (sv) * 2002-07-03 2004-03-23 Moelnlycke Health Care Ab Sårförband innefattande en icke-enzymatisk antioxidant
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
EP1644004A4 (de) 2003-06-20 2010-10-06 Ronald Aung-Din Topische therapie zur behandlung von migräne, muskelzerrungen, muskelspasmus, spastizität und verwandten zuständen
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
EP1732577B1 (de) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topische verabreichung von l-arginin zur verbesserung des aussehens von körper und haut
US20050202073A1 (en) * 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
AU2012201048B2 (en) * 2004-04-19 2013-06-06 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
WO2005102307A2 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060105950A1 (en) * 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7879942B2 (en) 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
ITMI20061918A1 (it) * 2006-10-06 2008-04-07 Nanovector S R L Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln
DE102007061873A1 (de) 2007-01-15 2008-07-17 Bayer Innovation Gmbh Kieselsol-Material zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien dessen Herstellung und Verwendung
JP5542665B2 (ja) * 2007-06-08 2014-07-09 サムヤン バイオファーマシューティカルズ コーポレイション マトリックス型経皮投与剤およびその製造方法
US8602961B2 (en) 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
CA2729346A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010022326A2 (en) * 2008-08-22 2010-02-25 Us Worldmeds Llc Transdermal delivery of apomorphine using microneedles
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
WO2012092528A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
MA33454B1 (fr) * 2009-06-24 2012-07-03 Strategic Science & Tech Llc Composition topique contenant de l'ibuprofène
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
EP2545905A1 (de) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
WO2017055337A1 (en) 2015-09-28 2017-04-06 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
JPWO2021235436A1 (de) * 2020-05-20 2021-11-25
IT202100009857A1 (it) 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2542334A (en) * 1946-04-24 1951-02-20 Corning Glass Works Condensation of siloxanes
US2490357A (en) * 1946-04-24 1949-12-06 Corning Glass Works Polymerization of siloxanes
US2676182A (en) * 1950-09-13 1954-04-20 Dow Corning Copolymeric siloxanes and methods of preparing them
US2927907A (en) * 1957-01-07 1960-03-08 Dow Corning Siloxane elastomers
US3002951A (en) * 1959-04-27 1961-10-03 Dow Corning Method of polymerizing cyclic diorganosiloxanes
US3186967A (en) * 1961-04-12 1965-06-01 Wacker Chemie Gmbh Method of preparing high molecular weight organosiloxane polymers
BE623603A (de) * 1961-10-16
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3509191A (en) * 1968-04-29 1970-04-28 Dow Corning Silacyclopentenes and a method for making same
US3697473A (en) * 1971-01-04 1972-10-10 Dow Corning Composition curable through si-h and si-ch equals ch2 with improved properties
JPS59130811A (ja) * 1983-01-17 1984-07-27 Nitto Electric Ind Co Ltd 粘着性貼付製剤用膏体
FR2541019B1 (fr) * 1983-02-10 1986-07-18 Mecelec Sa Procede optique pour determiner les dimensions d'un objet en mouvement relatif, et plus particulierement d'une piece de monnaie dans un appareil a pre-paiement, et dispositif pour sa mise en oeuvre
US4584355A (en) * 1984-10-29 1986-04-22 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-I
US4585836A (en) * 1984-10-29 1986-04-29 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-II
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4591622A (en) * 1984-10-29 1986-05-27 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product thereof
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
FI873429A (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone

Also Published As

Publication number Publication date
WO1996019956A1 (en) 1996-07-04
EP0800364B1 (de) 2003-03-19
US5939094A (en) 1999-08-17
EP0800364A4 (de) 1998-04-01
DE69530004T2 (de) 2004-03-04
EP0800364A1 (de) 1997-10-15
US5562917A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
DE69530004D1 (de) Transdermale verabreichung von apomorphin
DE69628448D1 (de) Transdermale verabreichungsform von flurbiprofen
DE69431209D1 (de) Transdermale prostaglandin-zusammensetzung
FI925727A (fi) Transdermal dosering av burprenorfin
DE69430377D1 (de) Nachbehandlung von laminierten vliesen
DE69817446D1 (de) Behandlung von diabetes
FI921598A (fi) Transdermal komposition
DK42093D0 (da) Administrationsmetode
FI955681A0 (fi) Masennuslääkkeen annostusmuoto
DK452288A (da) Clebopride-holdig transdermalt plaster
DE69319679T2 (de) Eingabe von Sonderbuchstaben
DE59500266D1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
NO973471D0 (no) Transdermal formulering
FI965204A0 (fi) Bromelaiinin lääkekäyttö
FI973362A0 (fi) Transdermaalinen formula
DE69221617D1 (de) Aufbereitung von flüssigkeit
DE69500881D1 (de) Oxidation von uranhexafluorid
DE69628672D1 (de) Transdermale verabreichung von risperidon mit kontrollierter geschwindigkeit
FI954422A0 (fi) Ferroseenin käyttö
DE69333009T2 (de) Transdermale verabreichung von ketorolac
DE59501871D1 (de) Monocarbonsäureamide von Polyaminen
DK36193D0 (da) Fremgangsmaade
DE69417915D1 (de) Reinigung von uranhexafluorid
DE69325271D1 (de) Hydrosilylierung von fullarenen
DE498468T1 (de) Transdermale applikation von nikotin.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee